Table 1 Association between the subclassification of pT2 stage and clinicopathological characteristics of patients

Sex

 Male

146/185 (78.9%)

149/195 (76.4%)

 Female

39/185 (21.1%)

46/195 (23.6%)

Age

  ≤ 60

73/185 (39.5%)

83/195 (42.6%)

  > 60

112/185 (60.5%)

112/195 (57.4%)

Smoking history

 No

109/185 (58.9%)

104/195 (53.3%)

 Yes

76/185 (41.1%)

91/195 (46.7%)

Drinking history

 No

111/185 (60.0%)

113/195 (57.9%)

 Yes

74/185 (40.0%)

82/195 (42.1%)

ECOG score

 0

129/185 (69.7%)

122/195 (62.6%)

 1

42/185 (22.7%)

54/195 (27.7%)

 2

14/185 (7.6%)

19/195 (9.7%)

Primary location

 Upper

83/185 (44.9%)

92/195 (47.2%)

 Middle

24/185 (13.0%)

25/195 (12.8%)

 Low

78/185 (42.2%)

78/195 (40.0%)

Borrmann type

 Type I–II

150/185 (81.1%)

157/195 (80.5%)

 Type III–IV

35/185 (18.9%)

38/195 (19.5%)

Pathological type

 Adenocarcinoma

134/185 (72.4%)

146/195 (74.9%)

 Mucinous/rare carcinoma

51/185 (27.6%)

49/195 (25.1%)

Histologic type

 Well and moderate

53/185 (28.6%)

54/195 (27.7%)

 Poor

132/185 (71.4%)

141/195 (72.3%)

Neural invasion

 Negative

174/185 (94.1%)

168/195 (86.2%)

 Positive

11/185 (5.9%)

27/195 (13.8%)

Lymphovascular invasion

 Negative

162/185 (87.6%)

163/195 (83.6%)

 Positive

23/185 (12.4%)

32/195 (16.4%)

pN stage

 N0

121/185 (65.4%)

110/195 (56.4%)

 N1

38/185 (20.5%)

45/195 (23.1%)

 N2

19/185 (10.3%)

25/195 (12.8%)

 N3

7/185 (3.8%)

15/195 (7.7%)

 Number of lymph node metastasis*

1.0 ± 2.1

1.6 ± 2.7

TNM stage

 I

121/185 (65.4%)

110/195 (56.4%)

 II

57/185 (30.8%)

70/195 (35.9%)

 IIIA

7/185 (3.8%)

15/195 (7.7%)

 Number of lymph node retrieved*

14.7 ± 6.8

14.5 ± 6.7

Adjuvant chemotherapy

 Without

107/185 (57.8%)

98/195 (50.3%)

 With

78/185 (42.2%)

97/195 (49.7%)

HER-2/neu expression

 Negative

152/185 (82.2%)

151/195 (77.4%)

 Positive

33/185 (17.8%)

44/195 (22.6%)

P53 expression

 Negative

89/185 (48.1%)

82/195 (42.1%)

 Positive

96/185 (51.9%)

113/195 (57.9%)

VEGF expression

 Negative

55/185 (29.7%)

49/195 (25.1%)

 Positive

130/185 (70.3%)

146/195 (74.9%)

EGFR expression

 Negative

65/185 (35.1%)

58/195 (29.7%)

 Positive

120/185 (64.9%)

137/195 (70.3%)

Initial LDH level (U/L)

  < 245

179/185 (96.8%)

190/195 (97.4%)

  ≥ 245

6/185 (3.2%)

5/195 (2.6%)

Maximal LDH level (U/L)

  < 245

96/185 (51.9%)

115/195 (59.0%)

  ≥ 245

89/185 (48.1%)

80/195 (41.0%)

Initial CEA level (ng/mL)

  < 3.5

143/185 (77.3%)

141/195 (72.3%)

  ≥ 3.5

42/185 (22.7%)

54/195 (27.7%)

Initial CA125 level (U/mL)

  < 35

179/185 (96.8%)

193/195 (99.0%)

  ≥ 35

6/185 (3.2%)

2/195 (1.0%)

Initial CA19-9 level (U/mL)

  < 39

179/185 (96.8%)

182/195 (93.3%)

  ≥ 39

6/185 (3.2%)

13/195 (6.7%)

Initial AFP level (ng/mL)

  < 7

181/185 (97.8%)

178/195 (91.3%)

  ≥ 7

4/185 (2.2%)

17/195 (8.7%)